
Opinion|Videos|January 20, 2025
Overview of Teplizumab for Delaying Onset and Progression of Type 1 Diabetes
Panelists discuss how teplizumab, the first FDA-approved disease-modifying therapy for Type 1 diabetes, can delay disease onset by targeting CD3+ T cells and preserving beta cell function in high-risk individuals.
Advertisement
Episodes in this series

Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
Two Alzheimer Disease Therapies to Watch at CTAD 2025: Lecanemab and Sabirnetug Updates
2
FDA Approves Deep Transcranial Magnetic Stimulation Device for MDD Treatment in Youth Ages 15 to 21, BrainsWay Announces
3
Reinterpreting WHI and Rethinking GSM: Insights from Caroline Mitchell, MD, MPH
4
FDA Clears First CGM-Integrated Basal Insulin Dosing Optimizer for Adults With Type 2 Diabetes
5






















































































































































































































































































